Related Experiment Video

Updated: Aug 6, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Targeted therapies in the treatment of urothelial cancers

Jeanny B Aragon-Ching1, Donald L Trump1

  • 1GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA.

Urologic Oncology
|April 4, 2017
PubMed

Insights

Systemic treatment for advanced bladder cancer has seen slow progress. Recent immunotherapy approvals and targeted therapy research offer new hope for improved patient outcomes in this area of unmet need.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Systemic treatment for locally advanced and metastatic bladder cancer has faced challenges over the past two decades.
  • Current systemic therapies are suboptimal, highlighting a significant unmet medical need in bladder cancer management.

Purpose of the Study:

  • To review recent advancements and ongoing clinical trials in the systemic management of advanced bladder cancer.
  • To explore emerging therapeutic pathways identified by The Cancer Genome Atlas project for targeted treatment strategies.

Main Methods:

  • Review of recent clinical trial data and research findings.
  • Analysis of The Cancer Genome Atlas (TCGA) project data for novel therapeutic targets.

Main Results:

  • Immunotherapy agents (atezolizumab, nivolumab) are now approved for second-line salvage therapy, indicating potential for improved outcomes.
  • Targeted therapies, including vascular endothelial growth factor (VEGF) inhibitors (ramucirumab, sunitinib, bevacizumab) and receptor tyrosine kinase inhibitors (EGFR, FGFR), show promise in ongoing trials.

Conclusions:

  • Recent approvals in immunotherapy mark a potential turning point for bladder cancer treatment.
  • Ongoing research into targeted therapies presents promising avenues for addressing the unmet medical needs in advanced bladder cancer.
Keywords:
AngiogenesisHER2Targeted therapyUrothelial cancer

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Integration of Electroporation in Urological Practice: Design and Evaluation of a New Transurethral Electrode04:45

Integration of Electroporation in Urological Practice: Design and Evaluation of a New Transurethral Electrode

Published on: March 20, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...